Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.53 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.46 |
| ▸ | KIF11 | P52732 | 1/20 | 0.45 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | DCLRE1B | Q9H816 | 1/20 | 0.42 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 2/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.40 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.40 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.38 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2299673 | 0.84 | KIF11 (0.55) | ESR2CYP11B2KIF11CYP11B1HSD17B1 | |
| SCHEMBL1774347 | 0.83 | TAAR1 (0.63) | TAAR1ESR2CYP11B2CYP17A1CYP3A4 | |
| SCHEMBL30285974 | 0.83 | ALDH1A1 (0.54) | TAAR1ESR2CYP11B2KIF11CYP11B1 | |
| SCHEMBL1042606 | 0.83 | ALDH1A1 (0.54) | TAAR1ESR2CYP11B2KIF11CYP11B1 | |
| SCHEMBL257619 | 0.80 | KIF11 (0.49) | TAAR1ESR2CYP11B2KIF11CYP11B1 | |
| SCHEMBL30068301 | 0.80 | TAAR1 (0.59) | TAAR1ESR2CYP11B2CYP17A1CYP3A4 | |
| SCHEMBL31147883 | 0.80 | TAAR1 (0.59) | TAAR1ESR2CYP11B2CYP17A1CYP3A4 | |
| SCHEMBL19665085 | 0.80 | TAAR1 (0.59) | TAAR1ESR2CYP11B2CYP17A1CYP3A4 | |
| SCHEMBL12384880 | 0.80 | RAB9A (0.44) | KIF11MAP4K4HSD17B1HSD17B2 | |
| SCHEMBL22591574 | 0.80 | ALOX5 (0.48) | TAAR1ESR2KIF11DCLRE1BMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150344503-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE, METHODS OF TREATMENT AND METHODS OF PREPARING SAME | INFINITY PHARMACEUTICALS INC (US) | 2015-12-03 | — | — | US | claimed |
| US-20180244700-A1 | METHODS OF TREATING A FATTY ACID AMIDE HYDROLASE-MEDIATED CONDITION | INFINITY PHARMACEUTICALS, INC. | 2018-08-30 | — | — | US | disclosed |
| US-9951089-B2 | Methods of treating a fatty acid amide hydrolase-mediated condition | INFINITY PHARMACEUTICALS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9951089-B2 | Methods of treating a fatty acid amide hydrolase-mediated condition | INFINITY PHARMACEUTICALS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9951089-B2 | Methods of treating a fatty acid amide hydrolase-mediated condition | INFINITY PHARMACEUTICALS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9149465-B2 | Isoxazolines as inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20150239912-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | INFINITY PHARMACEUTICALS, INC. | 2015-08-27 | — | — | US | disclosed |
| US-20150239912-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | INFINITY PHARMACEUTICALS, INC. | 2015-08-27 | — | — | US | disclosed |
| US-20150239912-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | INFINITY PHARMACEUTICALS, INC. | 2015-08-27 | — | — | US | disclosed |
| US-9034849-B2 | Fatty acid amide hydrolase inhibitors | INFINITY PHARMACEUTICALS, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| EP-2531511-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | Infinity Pharmaceuticals, Inc. (US) | 2012-12-12 | — | — | EP | disclosed |
| EP-2432771-A1 | ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | Infinity Pharmaceuticals, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| EP-2404607-A1 | Boronic acids and esters as inhibitors of fatty acid amide hydrolase | Infinity Pharmaceuticals, Inc. (US) | 2012-01-11 | — | — | EP | disclosed |
| US-20110201574-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | INFINITY PHARMACEUTICALS, INC. | 2011-08-18 | — | — | US | disclosed |
| US-20110201574-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | INFINITY PHARMACEUTICALS, INC. | 2011-08-18 | — | — | US | disclosed |
| US-20110201574-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | INFINITY PHARMACEUTICALS, INC. | 2011-08-18 | — | — | US | disclosed |
| WO-2011097233-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | INFINITY PHARMACEUTICALS, INC. (US) | 2011-08-11 | — | — | WO | disclosed |
| WO-2011097233-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | INFINITY PHARMACEUTICALS, INC. (US) | 2011-08-11 | — | — | WO | disclosed |
| US-20110028478-A1 | ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| WO-2010135360-A1 | ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201574-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | FAAH, FAAH2, FASN | TAAR1 2103/4885ESR2 3039/4885CYP11B2 3327/4885 |
| US-20110028478-A1 | ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, HRH2 | TAAR1 620/4885ESR2 2781/4885CYP11B2 721/4885 |
| US-20180244700-A1 | METHODS OF TREATING A FATTY ACID AMIDE HYDROLASE-MEDIATED CONDITION | FAAH, FAAH2, FASN | TAAR1 2133/4885ESR2 2277/4885CYP11B2 2852/4885 |
| US-20150344503-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE, METHODS OF TREATMENT AND METHODS OF PREPARING SAME | FAAH, FAAH2, ASAH1 | TAAR1 745/4885ESR2 4255/4885CYP11B2 772/4885 |
| US-20150239912-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | FAAH, FAAH2, FASN | TAAR1 2103/4885ESR2 3039/4885CYP11B2 3327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.